CG Oncology Inc. (CGON)
CGON trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/0001193125-26-079498-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CGON on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001991792 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.0M |
| Net income | -$161.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -3985.0% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1369.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-06 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 239 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.4% |
| 1 month | -14.3% |
| 3 months | -10.6% |
| Year to date | +49.7% |
| 1 year | +44.7% |
| From 52-week high | -23.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc | $91.63 | -7.69% | $5.8B |
| IMVT | Immunovant Inc. | $28.71 | -2.61% | $5.9B |
| SRRK | Scholar Rock Holding Corporation | $40.52 | -3.39% | $4.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $50.10 | -2.81% | $4.8B |
| IOVA | Iovance Biotherapeutics Inc. | $14.50 | -0.41% | $6.6B |
| ADPT | Adaptive Biotechnologies Corporation | $25.28 | -1.13% | $4.0B |
| RLAY | Relay Therapeutics Inc. | $17.36 | -3.45% | $3.8B |
| RGEN | Repligen Corporation | $175.42 | +1.69% | $8.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier